X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22) 22
humans (21) 21
female (19) 19
oncology (19) 19
ovarian cancer (13) 13
article (11) 11
middle aged (11) 11
adult (9) 9
aged (9) 9
cancer (8) 8
carcinoma (8) 8
chemotherapy (8) 8
health aspects (8) 8
mutation (8) 8
obstetrics & gynecology (8) 8
mutations (7) 7
ovarian neoplasms - genetics (7) 7
ovarian neoplasms - pathology (7) 7
retrospective studies (7) 7
women (7) 7
animals (6) 6
braf (6) 6
neoplasm staging (6) 6
ovarian neoplasms - mortality (6) 6
research (6) 6
survival (6) 6
braf mutation (5) 5
cystadenocarcinoma, serous - pathology (5) 5
neoplasm grading (5) 5
ovarian neoplasms - drug therapy (5) 5
prognosis (5) 5
bevacizumab (4) 4
cystadenocarcinoma, serous - genetics (4) 4
drug therapy (4) 4
genetic aspects (4) 4
gynecology and obstetrics (4) 4
kras (4) 4
membrane proteins (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
proteins (4) 4
therapy (4) 4
treatment outcome (4) 4
trial (4) 4
tumors (4) 4
abridged index medicus (3) 3
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
borderline tumors (3) 3
brca1 (3) 3
brca2 (3) 3
care and treatment (3) 3
carriers (3) 3
cystadenocarcinoma, serous - mortality (3) 3
diagnosis (3) 3
follow-up studies (3) 3
gene expression (3) 3
genes, brca1 (3) 3
genes, brca2 (3) 3
gynecologic-oncology-group (3) 3
hair cells (3) 3
hematology, oncology and palliative medicine (3) 3
male (3) 3
medicine & public health (3) 3
mice (3) 3
molecular targeted therapy (3) 3
neoplasm recurrence, local - mortality (3) 3
obstetrics and gynecology (3) 3
otorhinolaryngologic diseases (3) 3
ovary (3) 3
paclitaxel (3) 3
serous borderline tumor (3) 3
surgery (3) 3
survival analysis (3) 3
young adult (3) 3
zebrafish (3) 3
zebrafish proteins - metabolism (3) 3
angiogenesis inhibitors - therapeutic use (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
biomarkers, tumor - genetics (2) 2
brca (2) 2
calcium (2) 2
carboplatin (2) 2
carcinoma, ovarian epithelial (2) 2
cells (2) 2
clinical trials (2) 2
clinical trials as topic (2) 2
cystadenocarcinoma, serous - drug therapy (2) 2
deafness (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease models, animal (2) 2
endometrial cancer (2) 2
epithelial ovarian (2) 2
expression (2) 2
fallopian tube neoplasms - drug therapy (2) 2
families (2) 2
features (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Histopathology, ISSN 0309-0167, 09/2018, Volume 73, Issue 3, pp. 438 - 443
Aims The most common BRAF mutation in ovarian low‐grade serous neoplasms (LGSNs) involves substitution of valine by glutamic acid at position 600 (V600E).... 
low‐grade serous carcinoma | VE1 immunohistochemistry | ovary | BRAFV600E mutation | serous borderline tumour | Immunohistochemistry | Monoclonal antibodies | Genetic aspects | Metastasis | Gene mutations | Glutamate | Proteins | Glutamic acid | Carcinoma | Valine | Mutation | Paraffin | Metastases | Tumors | low-grade serous carcinoma
Journal Article
Journal Article
Current treatment options in oncology, 09/2018, Volume 19, Issue 11, p. 54
Low-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer, accounting for approximately 10% of cases of serous ovarian cancer. Patients... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 5594 - 5594
Journal Article
Gynecologic Oncology Reports, ISSN 2352-5789, 05/2019, Volume 28, pp. 120 - 123
Women with endometrial cancer (EC) frequently receive adjuvant paclitaxel and carboplatin (PC) chemotherapy. There is no standard first line chemotherapy at... 
Carboplatin | Retreatment | Endometrial cancer | Paclitaxel
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 01/2019, Issue 39, p. e141
The treatment of women with advanced-stage epithelial ovarian cancer (EOC) is aggressive surgical cytoreduction and a combination of platinum plus taxane... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e16535 - e16535
Journal Article
Gynecologic Oncology Reports, ISSN 2352-5789, 11/2017, Volume 22, Issue C, pp. 9 - 12
•Brain metastasis is an extremely rare secondary site of ovarian cancer metastasis.•Serous borderline tumor with brain metastasis has not been previously... 
Serous borderline tumor of the ovary | Serous borderline tumor | Brain metastasis | Ovarian cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.